Innovative Peptide Discovery by Lactocore Scientists Promises Breakthrough in Neurological Treatment

Lactocore, a US-German biotech startup founded by neuroscientists, has discovered a new, potentially safer, and more efficient way to treat depression, ADHD, and addictions. To achieve this, researchers turned to cow milk, a known source of soothing substances, and analyzed it with an AI-driven drug discovery platform. This led to the discovery of a short peptide , named LCGM-10, with strong stimulatory effects that rival those of caffeine, minus the infamous rebound. The research was published in Frontiers in Behavioral Neuroscience.

Milk is known to contain peptides , that can regulate brain functions by modulating neurotransmitter systems. Dr. Anton Malyshev, co-founder and CEO of Lactocore Group, earned his Ph.D. in neurophysiology by studying the effects of breast milk peptides. It was then that he realized the vast potential of milk as a source of safer and more effective drugs against a range of psychological and physiological conditions.

Together with his fellow researchers, he founded a biotech startup named Lactocore. The team applies structural bioinformatics and machine learning to identify promising regulatory peptides in milk and other natural sources, develop them into drug candidates, and ultimately bring next-generation therapies to market.

Lactocore’s most recent peer-reviewed study, published in Frontiers in Behavioral Neuroscience, used a proprietary computational algorithm to identify several novel peptides targeting the metabotropic glutamate receptor 5 (mGluR5), crucial for various brain-related illnesses. After chemical optimization, these peptides were tested in animal studies. The peptide named LCGM-10 emerged as a promising drug candidate for the treatment of ADHD, OCD, and conditions related to impulsive behavior, such as drug addiction and gambling, without the side effects associated with current therapies.

Dr. Malyshev highlighted the potential market impact of their findings: "The results warrant further studies of LCGM-10 as a prospective alternative to current drugs available to patients. This peptide can revolutionize medical care for people with attention deficit, obsessive-compulsive disorder, or addictions by offering a treatment that not only meets the high standards of efficacy demanded in today's market but does so while minimizing side effects. This balance is what the healthcare sector has been striving for, reflecting a growing demand for innovative solutions that ensure patient safety without sacrificing performance. We are aimed at propelling this and other research directions forward, fulfilling a market gap with significant potential for both patient benefit and industry advancement."

Committed to leveraging peptides for safer, more effective treatments, Lactocore's research encompasses a range of conditions, including neurological diseases, anxiety disorders, diabetes, and healthy life extension. With the advancement to a Series A funding round, Lactocore is set to continue its mission to transform patient care standards globally.

About Lactocore Group

Lactocore Group is an international biotech startup focused on pioneering research with milk peptides. Utilizing proprietary computational tools, Lactocore Group has discovered a range of promising milk-derived peptides, two of which have already demonstrated proof-of-concept in late-stage preclinical studies. As of today, Lactocore Group has filed four patent applications related to peptide therapeutic agents, with the most recent one submitted in 2023.